Two patients in Panama with an unusual triple infection overcome COVID-19
Two patients in Panama with triple infection: HIV, tuberculosis and SARS-CoV-2, surpassed COVID-19, reported this Friday the team of doctors and scientists treating these cases considered "unusual."
These were male patients aged 29 and 53, both from the province of Colón, who were diagnosed between last March and April and treated by a medical team from a public hospital in that region and scientists from the Institute of Scientific Research and Services of High Technology (INDICASAT-AIP).
Specialists consider that these "unusual" cases contribute information to the theory that coinfection with HIV, Tuberculosis and SARS-CoV-2 does not seem to worsen the results of COVID-19 infection, indicated the INDICASAT-AIP in a public statement.
The research entity maintained that the highest number of complicated cases of COVID-19 occurs in patients with comorbidities of chronic diseases, such as hypertension, diabetes, and cancer, in addition to those over 60 years of age, as evidenced by figures in Panama and other countries.
Research like these only reinforces the need for larger studies to understand pathophysiology, that is, the study of the functioning of an organism during the course of a disease, generating knowledge that can serve the global medical community, especially through its publication in a scientific journal of an international nature, the statement added.
UNUSUAL CASES
The first case corresponds to a 29-year-old man who arrived at the hospital at the end of March, and the second a 53-year-old man who was treated at the end of April, both with diagnoses of COVID-19, tuberculosis and HIV.
The treatment provided to combat the new coronavirus was devised based on the experience of physicians and the Solidarity Clinical Trial published by the World Health Organization (WHO) and included the use of antibiotics, anti-tuberculosis drugs, oxygen therapy and hydroxychloroquine.
The doctors considered the use of hydroxychloroquine to treat both cases because it was recommended at the time by the Solidarity Clinical Trial published by the WHO. Currently the evidence has suggested points against its use. To date, there have been no reports of similar patients with three concomitant infectious diseases, indicated the Panamanian scientific research entity.
Panama included the use of hydroxychloroquine in the health protocols last July after having withdrawn it in May as a result of the WHO paralyzing clinical trials based on a study that showed an increase in the deaths of patients treated with this drug.
The two unusual cases presented with triple infection of tuberculosis, HIV and SARS-CoV-2 registered in Panama were treated strategically and quickly, said INDICASAT-AIP statement.
Acute respiratory failure caused by SARS-CoV-2 was addressed immediately. The rapid implementation of this strategy by Panamanian doctors facilitated a rapid recovery despite the patients having a triple infection.
Specialists consider that these "unusual" cases contribute information to the theory that coinfection with HIV, Tuberculosis and SARS-CoV-2 does not seem to worsen the results of COVID-19 infection, indicated the INDICASAT-AIP in a public statement.
The research entity maintained that the highest number of complicated cases of COVID-19 occurs in patients with comorbidities of chronic diseases, such as hypertension, diabetes, and cancer, in addition to those over 60 years of age, as evidenced by figures in Panama and other countries.
Research like these only reinforces the need for larger studies to understand pathophysiology, that is, the study of the functioning of an organism during the course of a disease, generating knowledge that can serve the global medical community, especially through its publication in a scientific journal of an international nature, the statement added.
UNUSUAL CASES
The first case corresponds to a 29-year-old man who arrived at the hospital at the end of March, and the second a 53-year-old man who was treated at the end of April, both with diagnoses of COVID-19, tuberculosis and HIV.
The treatment provided to combat the new coronavirus was devised based on the experience of physicians and the Solidarity Clinical Trial published by the World Health Organization (WHO) and included the use of antibiotics, anti-tuberculosis drugs, oxygen therapy and hydroxychloroquine.
The doctors considered the use of hydroxychloroquine to treat both cases because it was recommended at the time by the Solidarity Clinical Trial published by the WHO. Currently the evidence has suggested points against its use. To date, there have been no reports of similar patients with three concomitant infectious diseases, indicated the Panamanian scientific research entity.
Panama included the use of hydroxychloroquine in the health protocols last July after having withdrawn it in May as a result of the WHO paralyzing clinical trials based on a study that showed an increase in the deaths of patients treated with this drug.
The two unusual cases presented with triple infection of tuberculosis, HIV and SARS-CoV-2 registered in Panama were treated strategically and quickly, said INDICASAT-AIP statement.
Acute respiratory failure caused by SARS-CoV-2 was addressed immediately. The rapid implementation of this strategy by Panamanian doctors facilitated a rapid recovery despite the patients having a triple infection.